Cargando…

One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study

OBJECTIVE: The aim the study was to calculate remission, recovery and relapse rates in first episode patients with schizophrenia (FES) vs. patients at a later phase (non-FES). METHODS: Thirty-two FES and 101 non-FES patients took part in the study. The assessment included testing at baseline and at...

Descripción completa

Detalles Bibliográficos
Autores principales: Fountoulakis, Konstantinos N., Panagiotidis, Panagiotis, Theofilidis, Antonis T., Nimatoudis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383004/
https://www.ncbi.nlm.nih.gov/pubmed/32702222
http://dx.doi.org/10.9758/cpn.2020.18.3.434
_version_ 1783563357408722944
author Fountoulakis, Konstantinos N.
Panagiotidis, Panagiotis
Theofilidis, Antonis T.
Nimatoudis, Ioannis
author_facet Fountoulakis, Konstantinos N.
Panagiotidis, Panagiotis
Theofilidis, Antonis T.
Nimatoudis, Ioannis
author_sort Fountoulakis, Konstantinos N.
collection PubMed
description OBJECTIVE: The aim the study was to calculate remission, recovery and relapse rates in first episode patients with schizophrenia (FES) vs. patients at a later phase (non-FES). METHODS: Thirty-two FES and 101 non-FES patients took part in the study. The assessment included testing at baseline and at 1 year with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression scale, State-Trait Anxiety Inventory (STAI), Udvalg for Kliniske Undersøgelser (UKU) scale, Simpson Angus, and General Assessment of Functioning (GAF) subscale. The statistical analysis included chi-square test and analysis of covariance. RESULTS: At baseline 15.62% FES vs. 10.89% non-FES patients were in remission; none of FES vs. 2.97% non-FES patients were in recovery. At endpoint, the respective figures were 12.50% vs. 25.00% and 3.12% vs. 3.96%. None of the differences in rates was significant between the two groups except from the percentage of patients being under medication (higher in the non-FES group). Baseline PANSS negative subscale (PANSS-N) was the only predictor of the outcome at endpoint. CONCLUSION: The current study reported very low rates of remission and recovery of patients with schizophrenia without any differences between FES and non-FES patients. One possibility is that the increased antipsychotic treatment compensates for the worsening of the illness with time. An accumulating beneficial effect of antipsychotic treatment suggested that early lack of remission is not prognostic of a poor outcome.
format Online
Article
Text
id pubmed-7383004
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean College of Neuropsychopharmacology
record_format MEDLINE/PubMed
spelling pubmed-73830042020-08-31 One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study Fountoulakis, Konstantinos N. Panagiotidis, Panagiotis Theofilidis, Antonis T. Nimatoudis, Ioannis Clin Psychopharmacol Neurosci Original Article OBJECTIVE: The aim the study was to calculate remission, recovery and relapse rates in first episode patients with schizophrenia (FES) vs. patients at a later phase (non-FES). METHODS: Thirty-two FES and 101 non-FES patients took part in the study. The assessment included testing at baseline and at 1 year with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression scale, State-Trait Anxiety Inventory (STAI), Udvalg for Kliniske Undersøgelser (UKU) scale, Simpson Angus, and General Assessment of Functioning (GAF) subscale. The statistical analysis included chi-square test and analysis of covariance. RESULTS: At baseline 15.62% FES vs. 10.89% non-FES patients were in remission; none of FES vs. 2.97% non-FES patients were in recovery. At endpoint, the respective figures were 12.50% vs. 25.00% and 3.12% vs. 3.96%. None of the differences in rates was significant between the two groups except from the percentage of patients being under medication (higher in the non-FES group). Baseline PANSS negative subscale (PANSS-N) was the only predictor of the outcome at endpoint. CONCLUSION: The current study reported very low rates of remission and recovery of patients with schizophrenia without any differences between FES and non-FES patients. One possibility is that the increased antipsychotic treatment compensates for the worsening of the illness with time. An accumulating beneficial effect of antipsychotic treatment suggested that early lack of remission is not prognostic of a poor outcome. Korean College of Neuropsychopharmacology 2020-08-31 2020-08-31 /pmc/articles/PMC7383004/ /pubmed/32702222 http://dx.doi.org/10.9758/cpn.2020.18.3.434 Text en Copyright © 2020, Korean College of Neuropsychopharmacology This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Fountoulakis, Konstantinos N.
Panagiotidis, Panagiotis
Theofilidis, Antonis T.
Nimatoudis, Ioannis
One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
title One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
title_full One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
title_fullStr One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
title_full_unstemmed One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
title_short One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
title_sort one-year outcome of first vs. later episode schizophrenia: a real-world naturalistic study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383004/
https://www.ncbi.nlm.nih.gov/pubmed/32702222
http://dx.doi.org/10.9758/cpn.2020.18.3.434
work_keys_str_mv AT fountoulakiskonstantinosn oneyearoutcomeoffirstvslaterepisodeschizophreniaarealworldnaturalisticstudy
AT panagiotidispanagiotis oneyearoutcomeoffirstvslaterepisodeschizophreniaarealworldnaturalisticstudy
AT theofilidisantonist oneyearoutcomeoffirstvslaterepisodeschizophreniaarealworldnaturalisticstudy
AT nimatoudisioannis oneyearoutcomeoffirstvslaterepisodeschizophreniaarealworldnaturalisticstudy